Butorphanol
Hepatic Tumor
Bibo WangSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Hepatic Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Tehran University of Medical Sciences | Phase 4 | BBB |
Eloxatin Shanghai Zhongshan Hospital | Phase 4 | BB |
ALBUMIN AGGREGATED Sirtex Medical | Phase 4 | BB |
CHLORHEXIDINE Changhua Christian Hospital | Phase 4 | BB |
FLUOROURACILUM Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Butorphanol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →